StockData
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)

Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –

Earnings

Lakefront Biotherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
Raised
Feb 23, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Lakefront Biotherapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Feb 23, 2026after the close–––Release
Q4 FY2024ended Dec 31, 2024Feb 12, 2025after the close–––Release
Q4 FY2023ended Dec 31, 2023Feb 23, 2024before the open–––Release
Q4 FY2022ended Dec 31, 2022Feb 24, 2023before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Lakefront Biotherapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
operating cash outflowQ1 FY202650–NewFeb 23, 2026
cash and financial investmentsFY20262.77 – 2.85–LoweredFeb 23, 2026
cash costsFY202635 – 40–LoweredFeb 23, 2026
Costs related to the ongoing TYK2 programFY202640–RaisedFeb 23, 2026
one-time restructuring cash impactFY2026125 – 175–NewFeb 23, 2026

Guidance history

Every forecast Lakefront Biotherapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Feb 23, 2026cash and financial investmentsFY20262.77 – 2.85Lowered
Feb 23, 2026Costs related to the ongoing TYK2 programFY202640Raised
Feb 23, 2026cash costsFY202635 – 40Lowered
Feb 23, 2026one-time restructuring cash impactFY2026125 – 175New
Feb 23, 2026operating cash outflowQ1 FY202650New
Feb 23, 2024cash burnFY2024280 – 320New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Lakefront Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?